When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Ozoralizumab - Wikipedia

    en.wikipedia.org/wiki/Ozoralizumab

    Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases. [1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.

  3. Single-domain antibody - Wikipedia

    en.wikipedia.org/wiki/Single-domain_antibody

    A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (V H) of a heavy-chain antibody, or of a common IgG.These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea.

  4. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

  5. Molnupiravir - Wikipedia

    en.wikipedia.org/wiki/Molnupiravir

    The international nonproprietary name of the drug was inspired by that of Thor's hammer, Mjölnir. The idea is that the drug will strike down the virus like a mighty blow from the god of thunder. [30] In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) approved moving molnupiravir into Phase I clinical trials for ...

  6. FDA Clears MoonLake's Nanobody Study For Arthritis Patients - AOL

    www.aol.com/news/fda-clears-moonlakes-nanobody...

    The FDA has signed off MoonLake Immunotherapeutics AG's (NASDAQ: MLTX) Phase 2 study of the nanobody sonelokimab in patients with active psoriatic arthritis (PsA). This is a global clinical study ...

  7. CDC advisers recommend RSV drug to protect babies ahead of ...

    www.aol.com/news/cdc-advisers-recommend-rsv-drug...

    The drug is an antibody injection given to infants up to 19 months old ahead of RSV season. Next, the CDC director is expected to recommend the shot.

  8. Bi-specific T-cell engager - Wikipedia

    en.wikipedia.org/wiki/Bi-specific_T-cell_engager

    Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.

  9. Babies should get recently approved drug for RSV, CDC says - AOL

    www.aol.com/news/babies-drug-prevents-rsv-cdc...

    Infants should get a recently approved drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, U.S. health officials said ...